Drugs / AGS-16M8F
last change Nov 2012 re-read 3 minutes ago

AGS-16M8F

Developed for
renal cell carcinoma
Investigated by
Agensys, Inc. · Astellas Pharma Inc

Trials 1

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01114230 Aug 2010 → Nov 2012 renal cell carcinoma Astellas Pharma Inc Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AGS-16M8F ClinicalTrials.gov intervention name — accepted as the source's own label NCT01114230 ↗